A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib Mesylate Versus Sorafenib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Therapy